Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0941 or GDC-0980 plus fulvestrant versus fulvestrant in AI-resistant advanced breast cancer
2010-023763-17Phase 2Completed
- Sponsor
- Genentech
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Fulvestrant + GDC-0941, Fulvestrant + GDC-0980 and Fulvestrant + placebo (3 arms). Primary endpoint: Progression-free survival. Started Jul 2011; status: completed.
02
Drugs
pictilisibapitolisibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-023763-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023763-17.